Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by macman1519on Jan 31, 2018 12:19am
63 Views
Post# 27468098

RE:RE:NMIBC

RE:RE:NMIBCChaching, u think pharma doesnt know that!!!!! ?? Only us schmucks have figured that out?????? Seek a jv and ALL OUR PROBLEMS ARE SOLVED TOMORROW, NOT IN TWO OR THREE YEARS LIKE THE CHOIR IS TRYING TO MAKE U BELIEVE SO THEY CAN GET ONE MORE PP THROUGH US!!!! quote=Quattro74]Yes, and nmibc is very lucrative indication for TLT to start. It's been estimated that we will cut the cost of treatments to these patients in half and still make billions $$ each year. That is before we get upgraded to supplant BCG. Insurance companies will love how much less bladder cancer will cost. 

enriquesuave wrote: As long as safety continues to be met in this PH1, there should be no reason to stop here and focus on another indication as some here are trying hard to scare people.  So far No other cancer treatment has 100% no recurrence at 3 months like we have so far with TLD-1433.  Good competing drugs which require many many more treatment sessions only show about 40% no recurrence at 3 months.  IMHO 2-3 treatments of TLD-1433 will be what it takes for patients to remain tumor free long term and have an immune response which will prevent further recurrence and progression to the muscle layer. Unheard of kind of results so far for these hard to treat BCG failed patients.   And yes GBM and Lung are next IMHO.


[/quote]

Bullboard Posts